Sachin G Pai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5628574/publications.pdf

Version: 2024-02-01

26 1,172 14 papers citations h-index

26 26 26 2630 all docs citations times ranked citing authors

21

g-index

#	Article	IF	CITATIONS
1	Wnt/beta-catenin pathway: modulating anticancer immune response. Journal of Hematology and Oncology, 2017, 10, 101.	6.9	448
2	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget, 2017, 8, 8910-8920.	0.8	108
3	<i>FGFR3-TACC3</i> fusion in solid tumors: mini review. Oncotarget, 2016, 7, 55924-55938.	0.8	103
4	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget, 2016, 7, 65364-65373.	0.8	99
5	Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 2577-2584.	1.9	66
6	Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget, 2016, 7, 75176-75184.	0.8	64
7	Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 858-866.	0.6	37
8	Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. Cancers, 2020, 12, 51.	1.7	37
9	Angiotensin receptor blockers. Journal of Hypertension, 2013, 31, 1669-1675.	0.3	34
10	Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2016, 10, 873.	2.0	33
11	Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research. Cancers, 2020, 12, 2651.	1.7	27
12	Novel therapeutic agents in the treatment of metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 99.	0.8	22
13	The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget, 2016, 7, 46734-46749.	0.8	17
14	Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 695-702.	0.6	17
15	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0152585.	1.1	14
16	The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis. Clinical Colorectal Cancer, 2019, 18, e280-e286.	1.0	14
17	Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition. Neoplasia, 2018, 20, 1236-1245.	2.3	12
18	Ethics and medico legal aspects of "Not for Resuscitation". Indian Journal of Palliative Care, 2010, 16, 66.	1.0	7

#	Article	IF	CITATIONS
19	Long-acting interferon for myeloproliferative neoplasms - an update. Expert Review of Hematology, 2016, 9, 915-917.	1.0	6
20	Abstract 2771: Correlation of tumor mutation burden and chemotherapy outcomes in colorectal cancer. , 2017, , .		4
21	Symptomatic Hypocalcemia in Primary Hyperaldosteronism: A Case Report. Journal of Korean Medical Science, 2009, 24, 1220.	1.1	1
22	Renal Medullary Carcinoma., 2016,, 31-40.		1
23	Germline pharmacogenomics of thymidylate synthase gene in patients with gastrointestinal malignancies treated with fluoropyrimidines-based chemotherapy regimens Journal of Clinical Oncology, 2019, 37, 545-545.	0.8	1
24	Outcomes of American Burkitt's Lymphoma in HIV and Non HIV Patients Treated with Rituxan-Hyper CVAD Regimen. a Single Center Retrospective Study. Biology of Blood and Marrow Transplantation, 2016, 22, S226.	2.0	0
25	Abstract 5261: Prognosis of baseline absolute lymphocyte count (ALC) and neutrophil to lymphocyte ratio (NLR) in patients with pancreatic adenocarcinoma. , 2015, , .		O
26	The correlation between DPYD*9A (c.85T > C) genotype and dihydropyrimidine dehydrogenase deficiency phenotype in patients with gastrointestinal malignancies treated with fluoropyrimidines: Updated analysis Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	0